<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Exicure, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Exicure, Inc.

    Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address oncology, inflammatory diseases and genetic disorders. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      David A. Giljohann
    • FOUNDED
      2009
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Lisaiceland Inc.

    Lisaiceland Inc.

    Lisaiceland is here to bring you a fully blockchained, democratized, healthcare AI...

    Lisaiceland is here to bring you a fully blockc...

    Amount Raised:    $10,752.00
    Fundraising Status:    EC
    Filing Type:    CF
    Gritstone Oncology, Inc.

    Gritstone Oncology, Inc.

    Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight mu...

    Gritstone Oncology is developing tumor-specific...

    Filing Type:    PU
    Simulations Plus, Inc.

    Simulations Plus, Inc.

    Simulations Plus, Inc. is the leading developer of Absorption, Distribution, Metab...

    Simulations Plus, Inc. is the leading developer...

    Filing Type:    PU
    Ocular Therapeutix, Inc.

    Ocular Therapeutix, Inc.

    Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company focused on ...

    Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a bi...

    Filing Type:    PU
    AMAG Pharmaceuticals, Inc.

    AMAG Pharmaceuticals, Inc.

    Headquartered in Waltham, Massachusetts, we develop and deliver innovative medicin...

    Headquartered in Waltham, Massachusetts, we dev...

    Filing Type:    PU
    Achieve Life Sciences, Inc.

    Achieve Life Sciences, Inc.

    Achieve is a specialty pharmaceutical company committed to advancing cytisinicline...

    Achieve is a specialty pharmaceutical company c...

    Filing Type:    PU
    BioCurity Pharmaceuticals Inc.

    BioCurity Pharmaceuticals Inc.

    BioCurity is a clinical stage biopharmaceutical company with a mission to material...

    BioCurity is a clinical stage biopharmaceutical...

    Amount Raised:    $177,391.00
    Fundraising Status:    EC
    Filing Type:    CF
    Vaccinex, Inc.

    Vaccinex, Inc.

    Vaccinex is a clinical-stage biotechnology company engaged in the discovery and de...

    Vaccinex is a clinical-stage biotechnology comp...

    Filing Type:    PU
    Synthorx, Inc.

    Synthorx, Inc.

    Synthorx is a biotechnology company focused on prolonging and improving the lives ...

    Synthorx is a biotechnology company focused on ...

    Filing Type:    PU
    Akari Therapeutics Plc

    Akari Therapeutics Plc

    Akari is a biopharmaceutical company focused on developing inhibitors of acute and...

    Akari is a biopharmaceutical company focused on...

    Filing Type:    PU
    Five Prime Therapeutics, Inc.

    Five Prime Therapeutics, Inc.

    Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to im...

    Five Prime Therapeutics, Inc. discovers and dev...

    Filing Type:    PU
    Corbus Pharmaceuticals Holdings, Inc.

    Corbus Pharmaceuticals Holdings, Inc.

    Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical c...

    Corbus Pharmaceuticals Holdings, Inc. is a Phas...

    Filing Type:    PU
    ©2025 National Investor Network. All Rights Reserved.